TABLE 3.
VT-1161 efficacy in murine vaginal candidiasis with wild-type C. albicans 3153A
| Treatment | Posttreatment CFUa |
Compound levelb |
||
|---|---|---|---|---|
| Day 1 | Day 4 | Plasma (μg/ml) | Vagina (μg/g) | |
| Vehicle | 1,290 (926–2,893) | 15,166 (12,875–23,292) | ||
| FLUc (25 mg/kg) | 0 (0–70); <0.0001 | 0 (0–70); <0.0001 | 0.040 (0.020) | 0.082 (0.046) |
| VT-1161 (4 mg/kg) | 0 (0–13); <0.0001 | 2790 (0–3739); <0.0001 | 0.83 (0.16) | 1.5 (0.3) |
| VT-1161 (10 mg/kg) | 25 (0–143); <0.0001 | 2790 (18–8500); 0.0002 | 4.0 (1.3) | 5.8 (1.0) |
| VT-1161 (25 mg/kg) | 0 (0–140); <0.0001 | 0 (0–108); <0.0001 | 12 (4) | 16 (3) |
a
Data are median (interquartile range) CFU/100 μl lavage fluid at 1 day or 4 days posttreatment; P value compared to that of vehicle using the Mann-Whitney U test (bold values indicate significance).
b
Data are mean (SD) levels 4 days posttreatment.
c
FLU, fluconazole.